Centers for Disease Control and Prevention and Control ...

National Center for Emerging and Zoonotic Infectious Diseases

Centers for Disease Control and Prevention Immunization Safety Office Update

Advisory Commission on Childhood Vaccines (ACCV) 06 September 2019

A. Patricia Wodi, MD Immunization Safety Office Centers for Disease Control and Prevention (CDC)

Disclaimer

The findings and conclusions in this presentation are those of the author and do not necessarily represent the official position of CDC

The use of product trade names is for identification purposes only

2

Topics

Presentations at June 2019 Advisory Committee on Immunization Practice meeting*

Selected publications

*

3

Human Papillomavirus Vaccine

ACIP Update ? Human Papillomavirus (HPV) Vaccine

Key Agenda Topics 9vHPV (Gardasil 9) Immunogenicity and Safety Trial in Mid-Adult Females

? 9vHPV is highly immunogenic and well tolerated in women aged 27-45 years

? >99% seroconversion rate for 9 HPV types

Overview of Health Economic Models for HPV Vaccination of Mid-Adults

Evidence to Recommendations (EtR) Framework

Work Group Considerations and Proposed Policy Options

5

ACIP Update ? Human Papillomavirus Vaccine Recommendations

Catch-up vaccination through age 26 years*

? Catch-up vaccination for persons who are not adequately vaccinated through age 26 years (harmonization of recommendation for males and females)

Vaccination of adults aged 27 years and older

? 27-45 years: HPV vaccination based on shared clinical decision making for individuals who are not adequately vaccinated

? > 45 years: Vaccine not licensed in this age group

*Replaces wording for special populations through age 26 years such as men who have sex with men, transgender persons and people with

immunocompromising conditions

6

 ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download